Amyloid plaque formation in the brain plays a central role in the cognitive dysfunction characteristic of Alzheimer's Disease (AD).
Currently approved treatments for AD are limited and only temper symptoms without preventing or reversing disease progression. To change this paradigm, a focus on targeting the molecular basis of pathogenesis has led to searches for secretase inhibitors, particularly of -secretase (BACE). 5 Additionally, with the implication of metals in AD pathogenesis, 6 new drugs such as clioquinol and PBT2 that attenuate metal localization have also made their way into clinical trials. 7 While general metal chelation strategies may address some of the underlying processes associated with AD, they have a shortcoming in their limited ability to differentiate toxic metals associated with A plaques from those associated with normal metal homeostasis.
We previously introduced the concept of a prochelator as an agent that does not interact with metal ions until activated to its chelator form under specific conditions, for example elevated H 2 O 2 levels.
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Here we present a peptide prochelator that is enzymatically activated by BACE to yield a high affinity copper chelator (Figure 1 ). The utilization of a prodrug design allows the metal-binding functionality to be activated at the site of A production and specifically target copper in the A -Cu complex. Furthermore, once copper is bound its reactivity to promote ROS formation via Fenton chemistry is significantly reduced.
To generate a prochelator that would be a good substrate for BACE and that would release a copper chelating agent as the product, we used the known APP Swedish mutant sequence (EVNLDAEF, representing residues 668-675 and abbreviated SW) as a blueprint, since it is a better substrate for BACE than native APP. 11 The cleavage site is located between the leucine and aspartic acid residues. For the prochelator SWH, we replaced the second glutamic acid of SW with a histidine so that BACE cleavage would release the chelator peptide CP, with the N-terminal sequence DAHF. Peptides with an N-terminal free amine and a histidine in the third position are known as ATCUN motifs (amino terminal Cu and Ni binding) and are found natively on human serum albumin (HSA), one of the proteins responsible for binding Cu 2+ in serum. 12 To facilitate concentration determination and product identification, residues WHDR and WADR were incorporated onto the ends of the SW peptide and the SWH prochelator peptide, 13 respectively, to give the final sequences in Table 1 . The H was changed to A in SWH to avoid metal binding. Peptides were prepared by standard Fmoc solid-phase peptide synthesis.
Conversion of SWH to CP was achieved by incubating SWH with BACE and analyzing aliquots at various time intervals by liquid chromatography-mass spectrometry (LC-MS). The tryptophan tag in both SWH and CP allowed for a direct comparison of peak areas at 280 nm on the LC trace, while the in-line electrospray mass spectrometer provided mass identification of the products to confirm that cleavage occurred at the intended location. This analysis provided initial rates of 0.2% per min for both SWH and SW at 155 µM substrate concentration, indicating that SWH is as good a substrate as SW for BACE (Supporting Information, SI).
Once activated, the cleavage product CP has a high affinity for Cu 2+ . Competition studies with nitrilotriacetic acid in HEPES buffer at pH 7.4 provide a conditional stability constant (K′) corrected for the ternary NTA(Cu)(HEPES) complex of 10 12.6 , which is similar to other reports on the ATCUN motif found in HSA.
14 In contrast, SWH at pH 7.4 is unable to compete with even the weak Cu 2+ ligand glycylglycine (SI). This result indicates that copper binding by prochelator SWH would be inconsequential in a biological system. The summary of relevant conditional stability constants provided in Table 1 predicts that CP should be able to strip Cu 2+ from A . The -secretase substrate has weak metal affinity, but after selective proteolytic cleavage, the product sequesters copper from A , preventing aggregation. When copper is coordinated to A it catalyzes production of ROS, but sequestration by CP prevents such deleterious reactions. . When the experiment is repeated using SWH as the competitor, fluorescence increases linearly with added SWH, confirming that the prochelator is unable to strip Cu 2+ from A , as predicted from the thermodynamic data.
By sequestering Cu 2+ from A , CP also displays an ability to inhibit Cu 2+ -induced A aggregate formation, as verified by the light-scattering turbidity assay shown in Figure 2 . As expected, SWH is unable to inhibit aggregate formation while CP shows a protective effect at 1:1 CP:Cu stoichiometry. This result is consistent with peptides of similar sequence reported by others. 16 Predictably, CP is not as effective at binding Zn 2+ and preventing Zn 2+ -induced aggregation. Importantly, the reaction mixture from SWH and BACE incubations (but not SW + BACE) is able to both prevent and disaggregate preformed A -Cu aggregates, as shown by the green bars in Figure 2 .
Along with sequestering copper and preventing aggregate formation, CP also shows an ability to prevent ROS formation promoted by copper and A -Cu species. Redox-active Cu 2+/+ can catalyze OH
• formation from H 2 O 2 in Fenton-like reaction cycles. 17 As shown in Figure 3 , CP effectively protects against copper-catalyzed OH
• formation, as determined by the deoxyribose assay, a result that is consistent with others in the literature on similar peptide sequences. 16, 18 SWH, on the other hand, offers only limited protection, even at concentrations as high as 100 µM. The observed response for SWH may be due to some radical quenching at high concentrations, but the data corroborate the inability of the prochelator to bind copper.
Under reducing conditions, the A -Cu complex reacts with O 2 to generate H 2 O 2 . 19 An Amplex Red assay was used to show that CP also prevents this ROS formation, whereas SWH does not show an inhibitory effect (see SI).
In summary, we present a prochelator SWH that, once activated by BACE, is able to sequester copper from A , prevent and disassemble aggregate formation, and protect against copperpromoted H 2 O 2 and OH
• formation. Because these activities require activation by BACE, an enzyme active in AD brains, this strategy imparts site specificity for chelating copper only when BACE activity is elevated. Because a peptide drug is unlikely to cross the blood brain barrier or withstand the multitude of proteases found in the blood, future work includes improving CP's drug-like properties. 
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